Drug class
18F-labelled synthetic amino acid PET radiotracer; diagnostic imaging agent
Mechanism of action
Transported into tumour cells primarily through amino acid transporters such as ASCT2 and LAT1. Increased uptake can identify recurrent prostate cancer tissue after treatment; it is not a therapeutic amino acid analogue.
General use cases
- PET imaging to detect suspected recurrent prostate cancer in adults with rising prostate-specific antigen (PSA) after prior treatment; imaging findings should be interpreted with clinical and other diagnostic data
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
